1. What is the biggest advantage of a Stemnexa-Rx™ treatment?
The biggest advantage of non-surgical Stemnexa procedure is, under the right circumstances, avoiding surgery.
The best example of this in the literature is with tennis elbow. It got that name because it was ruining tennis players’ careers. They couldn’t squeeze a racket or hit a backhand. Once this situation turns chronic it’s very difficult to treat. Even with surgical reconstruction, 20% of patients never return to normal.
Dr. McKenna – “We just published a case study about an Achilles’ tendon patient with a 10-year history of a chronic full thickness, intertendinous disruption that prevented her from playing tennis, shopping longer than 20 to 30 minutes or even walking on uneven terrain like cobblestone streets.
After one stem cell injection into the inner substance of her Achilles’ tendon, she was back playing tennis after 10 weeks, and at 7 months, she showed no signs of changes within the tendon on MRI. She had complete tendon homogeneity and was completely healed.”
In our practice, it’s common to for these patients to recover after STEMNEXA-Rx (non-surgical) without a splint or arm sling. They are typically doing stretches immediately after the injection. The day after that, they must ice their elbow. For the next several weeks, all they have to do is avoid heavy lifting, pushing or pulling. It’s common for these patients to regain normal function in 4 to 6 weeks.
2. What are the biggest advantages of Stemnexa-Sx™ (Surgical)?
The latest technological advances are utilized at McKenna Orthopedics to try and correct the problem and shorten the healing time. This also affects the overall complication rate. The best example is a big surgery like an ACL reconstruction. The average healing time for ACL surgery is 369 days and during that time, patients are at increased risk of rupture and failure.
McKenna Orthopedics ACL patients have healed in as little as 16 to 20 weeks after Stemnexa-Sx. They have greatly reduced complication risk and can return to their normal activities much sooner.
Don’t rely on pain management to mask the injury. Explore biologic therapies with a group committed to the most minimally invasive procedures that help the body heal naturally and effectively.
Another big advantage is lower post-surgery infection rates. The normal infection rate for orthopedic surgeries is between 1% and 3%. After performing over 3,000 surgeries with biologics, Dr. McKenna has not had a single instance of post-surgery infection, which is quite remarkable.
The technology utilized in Stemnexa-Sx also reduces post-surgery inflammation, which increases patient comfort and speeds up the onset of the regenerative healing process.
Lastly, the proprietary technology enables Dr. McKenna to reconstruct tendons like the ACL using the largest, strongest tendon replacement without having to weaken another part of the patient’s body, which happens when doctors remove part of one tendon to repair another one.
3. Is Stemnexa FDA approved?
All of the Stemnexa Bone Marrow Procedures performed in the U.S. today are same-day procedures that are compliant with CFR 21 Part 1271, falling under the same surgery exemption discussed in 1271.15 (b).
Amniotic tissue, such as the tissue used in Stemnexa, has been used since 1910 in the US and is now FDA-exempt for treating wounds and other conditions. It was first used for treating eye problems, primarily corneas and is still widely used in ophthalmology today.
The Bio-Mac bone marrow aspiration cannula and the AUTOSPIN Magellan centrifuge have received 501(k) clearances from the US FDA.